|
1
|
Heitzer E, Haque IS, Roberts CES and
Speicher MR: Current and future perspectives of liquid biopsies in
genomics-driven oncology. Nat Rev Genet. 20:71–88. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siravegna G, Mussolin B, Venesio T,
Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB,
Siu LL and Bardelli A: How liquid biopsies can change clinical
practice in oncology. Ann Oncol. 30:1580–1590. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thierry AR, El Messaoudi S, Gahan PB,
Anker P and Stroun M: Origins, structures, and functions of
circulating DNA in oncology. Cancer Metastasis Rev. 35:347–376.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mouliere F, Robert B, Arnau Peyrotte E,
Del Rio M, Ychou M, Molina F, Gongora C and Thierry AR: High
fragmentation characterizes tumour-derived circulating DNA. PLoS
One. 6:e234182011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bettegowda C, Sausen M, Leary RJ, Kinde I,
Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al:
Detection of circulating tumor DNA in early- and late-stage human
malignancies. Sci Transl Med. 6:224ra242014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Diaz LA Jr and Bardelli A: Liquid
biopsies: Genotyping circulating tumor DNA. J Clin Oncol.
32:579–586. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kastrisiou M, Zarkavelis G, Kougioumtzi A,
Sakaloglou P, Kostoulas C, Georgiou I, Batistatou A, Pentheroudakis
G and Magklara A: Development and validation of a targeted ‘Liquid’
NGS panel for treatment customization in patients with metastatic
colorectal cancer. Diagnostics (Basel). 11:23752021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Corcoran RB and Chabner BA: Application of
Cell-free DNA analysis to cancer treatment. N Engl J Med.
379:1754–1765. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang CC, Du M and Wang L: Bioinformatics
analysis for circulating cell-free DNA in cancer. Cancers (Basel).
11:8052019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tivey A, Church M, Rothwell D, Dive C and
Cook N: Circulating tumour DNA - looking beyond the blood. Nat Rev
Clin Oncol. 19:600–612. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Misale S, Yaeger R, Hobor S, Scala E,
Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M,
Siravegna G, et al: Emergence of KRAS mutations and acquired
resistance to anti-EGFR therapy in colorectal cancer. Nature.
486:532–536. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dasari A, Morris VK, Allegra CJ, Atreya C,
Benson AB III, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA,
et al: ct-DNA applications and integration in colorectal cancer: An
NCI colon and rectal-anal task forces whitepaper. Nat Rev Clin
Oncol. 17:757–770. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
14
|
Cervantes A, Adam R, Roselló S, Arnold D,
Normanno N, Taïeb J, Seligmann J, De Baere T, Osterlund P, Yoshino
T, et al: Metastatic colorectal cancer: ESMO Clinical Practice
Guideline for diagnosis, treatment and follow-up. Ann Oncol.
34:10–32. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mauri G, Vitiello PP, Sogari A, Crisafulli
G, Sartore-Bianchi A, Marsoni S, Siena S and Bardelli A: Liquid
biopsies to monitor and direct cancer treatment in colorectal
cancer. Br J Cancer. 127:394–407. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pascual J, Attard G, Bidard FC, Curigliano
G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD,
Montagut C, et al: ESMO recommendations on the use of circulating
tumour DNA assays for patients with cancer: A report from the ESMO
Precision Medicine Working Group. Ann Oncol. 33:750–768. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Heitzer E, Ulz P and Geigl JB: Circulating
tumor DNA as a liquid biopsy for cancer. Clin Chem. 61:112–123.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wan JCM, Massie C, Garcia-Corbacho J,
Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R and Rosenfeld N:
Liquid biopsies come of age: Towards implementation of circulating
tumour DNA. Nat Rev Cancer. 17:223–238. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tie J, Cohen JD, Wang Y, Christie M and
Simons K: Circulating tumor DNA analyses as markers of recurrence
risk and benefit of adjuvant therapy for stage III colon cancer.
JAMA Oncol. 5:1710–1717. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Reinert T, Henriksen TV, Christensen E,
Sharma S, Salari R, Sethi H, Knudsen M, Nordentoft I, Wu HT, Tin
AS, et al: Analysis of plasma cell-free DNA by ultradeep sequencing
in patients with stages I to III colorectal cancer. JAMA Oncol.
5:1124–1131. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Siravegna G, Marsoni S, Siena S and
Bardelli A: Integrating liquid biopsies into the management of
cancer. Nat Rev Clin Oncol. 14:531–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Douillard JY, Oliner KS, Siena S,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations
in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD,
Robitaille S, et al: K-ras mutations and benefit from cetuximab in
advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bardelli A and Pantel K: Liquid biopsies,
what we do know (yet). Cancer Cell. 31:172–179. 2017. View Article : Google Scholar : PubMed/NCBI
|
